Results 141 to 150 of about 767,219 (291)

Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study)

Technology in Cancer Research & Treatment
Objective: The prognosis of malignant tumors with peritoneal metastases and cancerous ascites has generally been poor, with limited treatment options.
Yingying Xu MS, Yuehong Kong MS, Yifu Ma MS, Meiling Xu MS, Jiabao Yang MS, Junjun Zhang PhD, Rongzheng Chen MS, Guangqiang Chen MS, Zhihui Hong MS, Xiangrong Zhao MS, Chenyang Zhang MS, Pengfei Xing MS, Liyuan Zhang MD, Peifeng Zhao MS   +13 more
doaj   +1 more source

Large‐cohort humanized NPI mice reconstituted with CD34 ⁺ hematopoietic stem cells are feasible for evaluating preclinical cancer immunotherapy [PDF]

, 2022
XiongFei Xu, Haihui Gu, Hongwei Li, Suizhi Gao, Xiaohan Shi, Jing Shen, Bo Li, Huan Wang, Kailian Zheng, Zhuo Shao, Peng Cheng, Zhanshan Cha, Siying Peng, Yongzhan Nie, Zhao-Shen Li, Shiwei Guo, Baohua Qian, Gang Jin, XiongFei Xu, Haihui Gu, Hongwei Li, Suizhi Gao, Xiaohan Shi, Jing Shen, Bo Li, Huan Wang, Kailian Zheng, Zhuo Shao, Peng Cheng, Zhanshan Cha, Siying Peng, Yongzhan Nie, Zhao-Shen Li, Shiwei Guo, Baohua Qian, Gang Jin   +35 more
openalex   +1 more source

Multi‐Omics Integration for Advancing Glioma Precision Medicine

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Gliomas are among the most malignant and aggressive tumors of the central nervous system, characterized by the absence of early diagnostic markers, poor prognosis, and a lack of effective treatments. Advances in high‐throughput technologies have facilitated a refined molecular classification of gliomas, incorporating genetic features. However,
Maria Guarnaccia, Valentina La Cognata, Giulia Gentile, Giovanna Morello, Sebastiano Cavallaro   +4 more
wiley   +1 more source

Association of Interleukin 7 Immunotherapy With Lymphocyte Counts Among Patients With Severe Coronavirus Disease 2019 (COVID-19) [PDF]

, 2020
Pierre François Laterre, Bruno François, Christine Collienne, Philippe Hantson, Robin Jeannet, Kenneth E. Remy, Richard S. Hotchkiss   +6 more
openalex   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source

The antitumor mechanism of immuno-flap treatment in a rat model of head and neck cancer

Cancer Immunology, Immunotherapy
Background Local recurrence after surgical resection is a major clinical challenge in patients with advanced head and neck cancer (HNC). We previously reported using transfer of a flap treated with dendritic cells (DCs) (“immuno-flap”) as a novel cancer ...
Hiroaki Mori, Yasuto Akiyama, Chie Maeda, Akari Kanematsu, Tadashi Ashizawa, Kazue Yamashita, Haruo Miyata, Akira Iizuka, Tomoatsu Ikeya, Yoshichika Yasunaga, Jun Araki   +10 more
doaj   +1 more source

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo, Deyou Peng, Zhouao Zhang, Mingjin Yang, Xinyan Guo, Tianyu Ma, Xiaoyu Huang, Mingming Xu, Linlin Fu, Yong Zhang   +9 more
wiley   +1 more source

Antibody response to COVID‐19 mRNA vaccine (Comirnaty) in myeloma patients treated with high‐dose melphalan and/or immunotherapy [PDF]

, 2021
Sandra Lockmer, Katarina Uttervall, Muhammad Kashif, Carina Svärd, Katarina Malmsten, Evellyn Fletcher‐Torres, Evren Alici, Johan Lund, Hareth Nahi   +8 more
openalex   +1 more source

Daratumumab Treatment for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): A Case Report

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune‐mediated neuropathy featuring progressive weakness, sensory deficits, and areflexia. While corticosteroids, intravenous immunoglobulin, and plasmapheresis are effective first‐line immunotherapies, a subset of patients remains treatment‐refractory.
Xueyu Zhang, Jianli Zhao, Xue Zhao, Xiaowei Hu, Zichun Xiao, Jie Wu, Xiaowen Li, Jing Xu, Yu‐Jing Li   +8 more
wiley   +1 more source

RRP9 Promotes Esophageal Squamous Cell Carcinoma Progression through E2F1 Transcriptional Regulation of CDK1

Advanced Biology, EarlyView.
The study reveals that RRP9 is abnormally highly expressed in ESCC tissues and is closely associated with poor prognosis in patients. Furthermore, it is found that RRP9 promotes ESCC progression through enhancing the E2F1‐mediated transcriptional regulation of CDK1.
Gang He, Yilong Wan, Yanbo Zhu, Bo Peng, Shengxiang Shao, Xinyi Zou, Zhenyu Han, Jiaxi Li, Sheng Ju, Xin Tong, Jun Zhao, Hansi Liang, Liuqing Zhang, Jiashi Xiong, Dong Jiang   +14 more
wiley   +1 more source